Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:37 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B
NCT01271868 · Medexus Pharma, Inc. · PHASE3 · terminated · last registry update 2021-03-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Medexus Pharma, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against F9 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-02-04Results posted on the registry: Genzyme, a Sanofi Company, fitusiran + factor concentrates (NCT03417245)
- 2022-01-24Phase 3 first posted: Shanghai Xinzhi BioMed Co., Ltd., Single dose intravenous injection of BBM-H901 (NCT05203679)
- 2021-12-21Results posted on the registry: Genzyme, a Sanofi Company, fitusiran + Bypassing agents (NCT03417102)
- 2021-12-14Phase 3 first posted: Takeda, TAK-330 + SOC 4F-PCC (NCT05156983)
- 2021-12-06Phase 3 first posted: Pfizer, PF-06741086 (NCT05145127)
- 2021-11-03Also stopped (terminated): IRCCS Policlinico S. Donato, Fibrinogen Concentrate Human + Prothrombin Complex Concentrate (NCT04434001)
- 2021-10-08Results posted on the registry: BioMarin Pharmaceutical, Valoctocogene Roxaparvovec (NCT03392974)
- 2021-08-09Results posted on the registry: Catalyst Biosciences, Coagulation Factor IX variant + Coagulation Factor IX variant (NCT03995784)
- 2021-07-30Results posted on the registry: Pfizer, Nonacog alfa (NCT04286412)
- 2021-06-11Results posted on the registry: Hoffmann-La Roche, Emicizumab (NCT03191799)
- 2021-04-30Phase 3 first posted: Octapharma, Octaplex (NCT04867837)
- 2021-03-01Results posted on the registry: Genentech, Inc., Emicizumab (NCT03361137)
- 2021-03-01Also stopped (terminated): Genentech, Inc., Emicizumab (NCT03361137)
- 2020-11-10Results posted on the registry: ISU Abxis Co., Ltd., ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg + BeneFIX (NCT03186677)
- 2020-09-24Phase 3 first posted: Emory University, Emicizumab + FEIBA (NCT04563520)
- 2020-08-28Results posted on the registry: Laboratoire français de Fractionnement et de Biotechnologies, Coagulation FVIIa (Recombinant) (NCT02448680)
- 2020-07-31Results posted on the registry: Bioverativ, a Sanofi company, rFIXFc (NCT02234310)
- 2020-06-16Phase 3 first posted: Hoffmann-La Roche, Emicizumab (NCT04431726)
- 2020-06-16Results posted on the registry: PTC Therapeutics, Ataluren (NCT00947193)
- 2020-06-16Also stopped (terminated): PTC Therapeutics, Ataluren (NCT00947193)
- 2020-05-19Results posted on the registry: Pfizer, SPK-9001 (NCT02484092)
- 2020-03-26Phase 3 first posted: BioMarin Pharmaceutical, valoctocogene roxaparvovec (NCT04323098)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision